Dean Investment Associates LLC boosted its position in CVS Health Corporation (NYSE:CVS) by 13.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 84,910 shares of the pharmacy operator’s stock after buying an additional 10,273 shares during the period. CVS Health Corporation makes up approximately 1.1% of Dean Investment Associates LLC’s investment portfolio, making the stock its 13th largest holding. Dean Investment Associates LLC’s holdings in CVS Health Corporation were worth $6,665,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. United Asset Strategies Inc. boosted its position in CVS Health Corporation by 6.3% in the first quarter. United Asset Strategies Inc. now owns 67,487 shares of the pharmacy operator’s stock valued at $5,298,000 after buying an additional 3,992 shares during the last quarter. Clifford Swan Investment Counsel LLC boosted its position in CVS Health Corporation by 16.8% in the first quarter. Clifford Swan Investment Counsel LLC now owns 3,627 shares of the pharmacy operator’s stock valued at $285,000 after buying an additional 522 shares during the last quarter. Alambic Investment Management L.P. purchased a new stake in CVS Health Corporation in the first quarter valued at approximately $777,000. Oxford Asset Management purchased a new stake in CVS Health Corporation in the first quarter valued at approximately $3,995,000. Finally, Bahl & Gaynor Inc. boosted its position in CVS Health Corporation by 1.1% in the first quarter. Bahl & Gaynor Inc. now owns 14,922 shares of the pharmacy operator’s stock valued at $1,171,000 after buying an additional 167 shares during the last quarter. Hedge funds and other institutional investors own 81.55% of the company’s stock.
A number of research analysts have issued reports on CVS shares. Jefferies Group LLC boosted their price target on CVS Health Corporation from $82.00 to $86.00 and gave the company a “hold” rating in a report on Friday. Needham & Company LLC started coverage on CVS Health Corporation in a report on Tuesday, June 27th. They issued a “hold” rating for the company. Guggenheim reissued a “buy” rating on shares of CVS Health Corporation in a report on Monday, July 3rd. Leerink Swann set a $90.00 price target on CVS Health Corporation and gave the company a “buy” rating in a report on Tuesday, June 27th. Finally, BidaskClub raised CVS Health Corporation from a “sell” rating to a “hold” rating in a report on Wednesday, August 2nd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $90.35.
CVS Health Corporation (NYSE:CVS) traded up 0.64% during trading on Friday, hitting $83.17. The stock had a trading volume of 7,483,230 shares. CVS Health Corporation has a one year low of $69.30 and a one year high of $90.85. The firm has a market cap of $84.55 billion, a price-to-earnings ratio of 16.57 and a beta of 0.92. The stock’s 50-day moving average is $78.92 and its 200 day moving average is $78.97.
CVS Health Corporation (NYSE:CVS) last released its quarterly earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.31 by $0.02. The company had revenue of $45.69 billion during the quarter, compared to analysts’ expectations of $45.36 billion. CVS Health Corporation had a return on equity of 17.47% and a net margin of 2.93%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.32 earnings per share. Equities analysts anticipate that CVS Health Corporation will post $5.88 earnings per share for the current year.
In other news, Director Richard J. Swift sold 2,500 shares of CVS Health Corporation stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $79.62, for a total value of $199,050.00. Following the completion of the sale, the director now owns 3,258 shares of the company’s stock, valued at $259,401.96. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Larry J. Merlo sold 241,150 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $83.07, for a total value of $20,032,330.50. Following the sale, the insider now directly owns 299,255 shares of the company’s stock, valued at approximately $24,859,112.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 611,660 shares of company stock valued at $49,492,596. Company insiders own 0.61% of the company’s stock.
About CVS Health Corporation
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with our FREE daily email newsletter.